To develop a potent LRA for the functional cure of HIV-1 infection with the “shock and kill” strategy, we adapted the logic of the virus itself and generated a recombinant Tat-R5M4 that exerts its specificity and efficiency for latency activation and also shows great potential to become a protein drug, especially when used in combination with HDACi. The gene discussed is TAT; the disease is HIV-1 infection.